NeuroStar Advanced Therapy Wins 2023 Bulldog PR Award For Partnership With Drew Robinson, Mental Health Advocate and Former MLB Player
Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression Treatment MALVERN, Pa., July 11, 2023…
Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression Treatment MALVERN, Pa., July 11, 2023…
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed…
Award Recognizes Efforts to Raise Awareness Around Non-Drug Depression Treatment MALVERN, Pa., July 11, 2023…
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed…
Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company BASKING…
Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company BASKING…
— Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of…
— Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of…
The trial will assess the safety and preliminary efficacy of Salarius’ novel targeted protein degrader…
The trial will assess the safety and preliminary efficacy of Salarius’ novel targeted protein degrader…
Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE:…
Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE:…
SAN FRANCISCO, July 11, 2023 (GLOBE NEWSWIRE) — Artificial intelligence and machine learning innovator McClintock…
SAN FRANCISCO, July 11, 2023 (GLOBE NEWSWIRE) — Artificial intelligence and machine learning innovator McClintock…
HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that…
HAMPTON, N.J., July 11, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that…
Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to…
Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to…
Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months…
Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months…